Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis

ClinicalTrials.gov ID: NCT00035958

Public ClinicalTrials.gov record NCT00035958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Toward Improved Understanding of Pathogenesis and Treatment of Childhood Onset Dermatomyositis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Juvenile dermatomyositis (JDMS) is one of the most serious of the childhood rheumatic diseases. The theory behind this trial is that early introduction of etanercept or methotrexate will prove to be effective in the treatment of JDMS. Pretreatment muscle biopsies, we believe there will be abnormalities in the blood vessels that will be correlated with worse physical strength and daily functional ability. The long-term goal is to improve the treatment of this serious childhood onset rheumatic disease and to better understand the pathogenic mechanism for the development of the vasculopathy (disorder of blood vessels) of JDMS. Identification of the specific mechanism of the vasculopathy may allow for the rational introduction of biologic treatments focused on vascular growth.

Study identification

NCT ID: NCT00035958
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Enrollment: 75 participants

Conditions and interventions

Conditions

Dermatomyositis

Interventions

Drug

Eligibility (public fields only)

Age range: 4 Years to 16 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2002
Primary completion: Jul 31, 2002
Completion: Jul 31, 2002
Last update posted: Jul 31, 2013

2002

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Cincinnati Childrens Hospital Medical Center	Cincinnati	Ohio	45229	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00035958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 31, 2013 · Synced Sep 13, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00035958 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →